Artículos por temáticas

Targeting Alzheimer's disease with gene and cell therapies

Loera-Valencia R, Piras A, Ismail MAM, Manchanda S, Eyjolfsdottir H, Saido TC, Johansson J, Eriksdotter M, Winblad B, Nilsson P.

J Intern Med. 2018 Jul;284(1):2-36. doi: 10.1111/joim.12759.

Change in Fitness and the Relation to Change in Cognition and Neuropsychiatric Symptoms After Aerobic Exercise in Patients with Mild Alzheimer's Disease

Sobol NA, Dall CH, Høgh P, Hoffmann K, Frederiksen KS, Vogel A, Siersma V, Waldemar G, Hasselbalch SG, Beyer N.

J Alzheimers Dis. 2018;65(1):137-145. doi: 10.3233/JAD-180253.

Prevention of late‑life dementia: what works and what does not

Tipton PW, Graff-Radford NR.

Pol Arch Intern Med. 2018 May 30;128(5):310-316. doi: 10.20452/pamw.4263. Epub 2018 May 16.

Alzheimers' disease and caregiving: a meta-analytic review comparing the mental health of primary carers to controls

Ma M, Dorstyn D, Ward L, Prentice S.

Aging Ment Health. 2018 Nov;22(11):1395-1405. doi: 10.1080/13607863.2017.1370689. Epub 2017 Sep 5.

Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition

Grizzanti J, Corrigan R, Casadesus G.

J Alzheimers Dis. 2018;66(1):11-23. doi: 10.3233/JAD-180433.

Alzheimer's Disease and Parkinson's Disease: A Review of Current Treatment Adopting a Nanotechnology Approach

Trompetero A, Gordillo A, Del Pilar MC, Cristina VM, Bustos Cruz RH.

Curr Pharm Des. 2018;24(1):22-45. doi: 10.2174/1381612823666170828133059.

Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease

Wolinsky D, Drake K, Bostwick J.

Curr Psychiatry Rep. 2018 Oct 27;20(12):117. doi: 10.1007/s11920-018-0978-8.

Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer's Disease: Are We There Yet?

Raikwar SP, Thangavel R, Dubova I, Ahmed ME, Selvakumar PG, Kempuraj D, Zaheer S, Iyer S, Zaheer A.

J Alzheimers Dis. 2018;65(2):321-344. doi: 10.3233/JAD-180422.

Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects

Kozin SA, Barykin EP, Mitkevich VA, Makarov AA.

Biochemistry (Mosc). 2018 Sep;83(9):1057-1067. doi: 10.1134/S0006297918090079.

New hope for Alzheimer's dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis

Stahl SM.

CNS Spectr. 2018 Oct;23(5):291-297. doi: 10.1017/S1092852918001360.

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease

Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMa

N Engl J Med. 2018 Jan 25;378(4):321-330. doi: 10.1056/NEJMoa1705971.

Modulation of γ- and β-Secretases as Early Prevention Against Alzheimer's Disease

Voytyuk I, De Strooper B, Chávez-Gutiérrez L.

Biol Psychiatry. 2018 Feb 15;83(4):320-327. doi: 10.1016/j.biopsych.2017.08.001. Epub 2017 Aug 10.

Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy

Verma S, Kumar A, Tripathi T, Kumar A.

J Pharm Pharmacol. 2018 Aug;70(8):985-993. doi: 10.1111/jphp.12919. Epub 2018 Apr 16.

Precision pharmacology for Alzheimer's disease

Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Wood

Pharmacol Res. 2018 Apr;130:331-365. doi: 10.1016/j.phrs.2018.02.014. Epub 2018 Feb 16.

A review of clinical treatment considerations of donepezil in severe Alzheimer's disease

Adlimoghaddam A, Neuendorff M, Roy B, Albensi BC.

CNS Neurosci Ther. 2018 Oct;24(10):876-888. doi: 10.1111/cns.13035. Epub 2018 Jul 29.